Healthcare / BiotechnologyNasdaqCM
$3.48
-0.02 (-0.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-158.9M · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$145M
P/E
1.7x
↓EV/EBITDA
2.8x
↓ROE
-0.0%
↓Gross Margin
29.6%
↓Debt/Equity
-0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+24.7%
FCF CAGR
—
FCF margin
-67.6%
FCF / Net income
-671.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $114.2M · net income $115000.0 · FCF $-77.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $114.2M | $114.2M | $103.5M | $156.3M | $98.0M | $295.7M | $88.2M | $150.0M | $36.8M | $42.9M | $22.6M | $24.8M | $7.0M | $3.0M | $16.0M | $2.8M | $3.4M | $3.3M |
| Net Income | $115000.00 | $115000.00 | $-227.2M | $-245.8M | $-220.1M | $-28.7M | $-182.9M | $-111.6M | $-162.0M | $-120.7M | $-127.0M | $-87.9M | $-42.5M | $-30.1M | $-11.3M | $-23.3M | $-21.9M | $-30.3M |
| EBITDA | $62.2M | $62.2M | $-101.3M | $-145.9M | $-161.8M | $32.5M | $-110.1M | $-63.5M | $-117.5M | $-97.8M | $-102.5M | $-78.7M | $-41.7M | $-24.4M | $-5.1M | $-16.8M | $-18.3M | $-23.6M |
| EPS | — | — | -10.59 | -13.75 | -15.64 | -2.20 | -20.61 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 29.6% | 29.6% | -50.8% | -52.1% | -101.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -18.0% | -18.0% | -120.3% | -102.4% | -183.9% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | -620.9% | -820.3% | -42.2% | -692.6% | -647.5% | -830.1% |
| Net Margin | 0.1% | 0.1% | -219.6% | -157.2% | -224.5% | -9.7% | -207.4% | -74.3% | -440.5% | -281.5% | -562.6% | -354.1% | -608.9% | -987.5% | -71.0% | -844.6% | -652.0% | -909.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | -0.21 | -0.21 | -0.29 | -0.55 | -1.28 | 0.37 | -0.09 | -0.06 | -0.08 | -1.88 | -3.34 | 1.62 | 0.21 | — | — | — | — | — |
| Current Ratio | 0.38 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-77.2M | $-77.2M | $-158.9M | $-234.2M | $-228.4M | $-23.7M | $-142.6M | $-23.3M | $-134.7M | $-97.3M | $-92.5M | — | $-41.1M | $-20.3M | $909160.00 | $-16.3M | $-14.9M | $-24.4M |
| Returns | ||||||||||||||||||
| ROE | -0.0% | -0.0% | 69.6% | 153.3% | 359.1% | -83.4% | 89.8% | 49.5% | 94.0% | 159.2% | 324.6% | -124.3% | -184.6% | 671.2% | 64.3% | 111.7% | 148.9% | 178.6% |
| Valuation | ||||||||||||||||||
| P/E | 1.70 | 1.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 2.83 | 2.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 10.4% | 10.4% | -33.8% | 59.5% | — | 235.3% | -41.2% | 307.9% | -14.2% | 89.9% | -9.0% | 255.7% | 129.1% | -80.9% | 479.2% | -18.0% | 0.8% | — |
| EPS Growth | — | — | 23.0% | 12.1% | — | 89.3% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-10.59 → n/d
Residual
+1.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.